Key points
- The pharmaceutical industry in Himachal Pradesh is facing a crisis due to raw material price increases of 40% to 150%.
- The crisis is affecting production and supply chains in Baddi, Solan, impacting both domestic and export markets.
- The Indian Drug Manufacturers Association has requested the Central Government to include key raw materials under the Essential Commodities Act.
The pharmaceutical industry in Himachal Pradesh is experiencing a major crisis due to rapidly increasing raw material prices, with costs rising by between 40% and 150%. This has disrupted production and supply chains, affecting both domestic sales and exports.
The price increases affect Active Pharmaceutical Ingredients (APIs), chemicals, and packaging materials. Specifically, the cost of acetone, methanol, and isopropyl alcohol has risen by 40% to 150%, according to reports.
Sumeet Singhla, Member of the National Executive of the Indian Drug Manufacturers Association (IDMA), stated that “The sharp rise in raw material prices has put the pharmaceutical industry under heavy pressure.”
Increased production costs are a direct result of these price hikes. Reports also indicate that delays in API supply have occurred, with one report noting some companies are facing penalties and damages as a result.
The IDMA has formally requested the Central Government to intervene. They have “Demanded that the central government consider including critical pharma raw materials under the Essential Commodities Act.”
Delays in supplying drugs to government and multinational companies are also causing financial losses and contractual liabilities for pharmaceutical firms. The production and supply of essential medications like paracetamol, metformin, and drugs used to treat heart disease have been affected.
IDMA alleges that some API manufacturers and traders accepted orders at fixed rates but then failed to deliver on time. Sumeet Singhla said, “For the past six months, some API manufacturers and traders have not delivered goods on time despite accepting orders at fixed rates.”
The issues are concentrated in the Baddi area of Solan, a key pharmaceutical manufacturing hub within Himachal Pradesh.